Speciality Medicines Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 21,000 (1%) | — | ₹3 Cr |
| NII (HNI) | — | 1,089,000 (46%) | — | ₹1,350 Cr |
| Retail | — | 1,090,000 (46%) | — | ₹1,352 Cr |
| Market Maker | — | 150,000 (6%) | — | ₹19 Cr |
| Σ Total | — | 2,350,000 (100%) | — | ₹29,140 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹124,000 |
| Retail (Max) | 13 | 13,000 | ₹1,612,000 |
| S-HNI (Min) | 14 | 14,000 | ₹1,736,000 |
| B-HNI (Min) | 67 | 67,000 | ₹8,308,000 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 37 | 59 | 28 |
| EBITDA | 7 | 9 | 5 |
| Profit After Tax | 6 | 9 | 3 |
| Net Worth | 36 | 30 | 15 |
| Total Assets | 46 | 40 | 23 |
| Reserves & Surplus | 30 | 24 | 10 |
| Total Borrowing | 5 | 5 | 3 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Setting up of Research and Development (R&D) Center – 13.31
- Product registration in the international markets – 2.89
- Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company – 1.66
- To Meet Working Capital Requirements – 8.00
- General Corporate Purpose –
Company Overview
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets.
The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations and inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets.
Through wide-ranging distribution channels, the company has built a trusted reputation with clients across more than 20 states in India and over 35 countries worldwide.
Speciality Medicines Limited offers over 650 products (as of July 31, 2024) under the unregistered category, with a particular focus on therapeutic areas like:
- Oncology
- Immunology
- Neurology
- Rare Diseases
Additionally, the company’s product range includes human and animal medicines, vaccines, and plasma products — all sourced from manufacturers that comply with global quality standards like EUGMP and PICS.
Global Expansion and Registrations
As of July 31, 2024, Speciality Medicines Limited has:
- 1 plasma product registered in Bolivia
- 127 products under registration across 8 countries
As of July 31, 2024, Speciality Medicines Limited employs a team of 20 permanent employees across various departments, contributing to the company’s smooth and efficient operations.